Other News

Physiomics will present on “Modelling the responses of populations of cancer cells to therapeutic radiation exposure”, on 5th September at the 5th International Systems Radiation Biology Workshop in Oxford.  Professor David Fell, Co-Founder and Scientific Advisory Board member, will show recent applications of the Virtual Tumour platform to forecast the outcome of combinations of radiation treatment with an anti-cancer drug. ...

Physiomics will present a workshop on “Applications of Physiomics’ Virtual Tumour to optimize the outcomes of xenograft experiments”, on 27th November at the 4th PK/PD Summit in Frankfurt. This workshop will review the available PK/PD models to simulate and analyze xenograft experiments and will present the features and the scientific and economic benefits of Physiomics’ Virtual Tumour cell population model. The workshop will include the...

Physiomics is an AIM – listed Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our Virtual Tumour technology is used by pharmaceutical and biotechnology companies to optimise drug dosing and scheduling regimens for pre-clinical studies.  The company is now starting to develop a clinical version of Virtual Tumour to optimise regimens in human patients. We seek to recruit a Senior Scientist...

Dr Frances Brightman and Dr Eric Fernandez have both been accepted to present at this years PAGE Meeting in Venice. They will show an update, respectively on the three-dimensional tumour cell cultures and on the anti cancer drug combination database research programs. Please click here for more information on the conference. ...

  “Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to optimize the outcomes of xenograft experiments”, ahead of the 2012 PAGE meeting. This workshop will review the available PK/PD models to simulate and analyze xenograft experiments and will present the features and the implementation of Physiomics’ Virtual Tumour technology with a previously published case study (for details click here). The workshop will...

Dr Frances Brightman has been accepted to present Abstract Number: 4942 at this years AACR Annual Meeting in Chicago. Please click here for more information on the conference. ...

We are delighted to announce that Mark Chadwick, CEO at Physiomics Plc has been accepted to present at this year’s biopartnering and investment conference. Read more about the conference. ...

Dr Mark Chadwich has been accepted to present at the BIO-Europe Spring conference this year. Read more about the conference ...

Dr Mark Chadwick has been accepted to give a presentation during the second pre-clinical session at 2.10pm at EPIC this year. Read more about the conference ...

Physiomics is an Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our models are based on sets of mathematical equations that simulate key biological processes, and are used by pharmaceutical companies to accelerate their internal drug discovery and development programs. We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development....